Jim Cramer on Structure Therapeutics: "I Don't Want to Touch It"

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the stocks on Jim Cramer’s radar recently. When a caller inquired about the stock, Cramer commented:

“Oh, okay, so this is a, they have a deal with Roche, and therefore, I think it’s a legitimate idea, but, boy, the stock fully reflects that deal. I don’t want to touch it. Lilly is still the gold standard.”

Structure Therapeutics Inc. (NASDAQ:GPCR) develops oral small-molecule drugs to treat chronic conditions like obesity and pulmonary fibrosis.

While we acknowledge the potential of GPCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.